Lifeboat Foundation

After getting a considerable success in convincing scientists and investors, in the last decades, that undoing aging through a damage repair approach is possible and desirable, Aubrey de Grey is turning his advocacy efforts to politicians. In this video, he explains why.

https://thelongevityforum.com/
Aubrey de Grey delivers a keynote on the next steps for longevity for policy makers.

Continue reading “Aubrey de Grey, CSO, SENS, ‘Scientists, check — Investors, check — Next up, policy makers’” »

The company’s machine learning-based tool applies advanced algorithms to Maccabi’s existing electronic patient data to identify unvaccinated individuals at highest risk of developing serious flu-related complications. These could include elderly people; those with uncontrolled chronic diseases or respiratory diseases; long-term smokers; those that are immunodeficient or have diabetes; or children, explained Dr. Jeremy Orr, CEO of EarlySign.

The EarlySign investigational algorithm flags these individuals, who are then contacted by their healthcare providers and encouraged to come into the clinic and be vaccinated. Patients can be contacted by phone, text message or even snail mail, depending on their communication preferences and the methods offered by their clinics.

Orr noted that the program is especially important this year when many people have already died from the flu in Israel and the virus is expected to take an exceptionally heavier toll than usual this year.

Science is enabling women to have children later in life as new technologies transform IVF success rates. But an increasingly globalised IVF trade also poses dangers.

Science is changing how and when families are made. Women are going to be able to have both career and family in a way that we’ve never seen before. New technologies are transforming IVF success rates. AI allows us to look at features of the embryo invisible to the human eye.

Continue reading “How science is changing the nature of families | The Economist” »

Newer, less invasive tests are helping scientists isolate genomic alterations.

BY HEATHER MILLAR

As an outbreak of a new virus in China spreads, U.S. officials will start screening passengers arriving at select U.S. airports.

Nagoya University researchers say they have designed a laser diode that emits the shortest-wavelength ultraviolet light to-date, with potential applications in disinfection, dermatology, and DNA analyses.

Mice cured of MRSA, raising hopes of treating antibiotic-resistant bacteria.

Recently published an article on Deep Learning.

Examining the visual acuity of children who are younger than three years old is important for the early discovery of abnormal visual development, potential ophthalmic diseases, and neurological disease.

If the visual abnormal development is not diagnosed in time, later development will be affected, but performing visual examination in children is challenging due to their lack of understanding of instructions. Evaluating the visual acuity of children remains difficult since many children are unable to effectively express their understanding, especially with respect to directions (i.e., up, down, left and right). In addition, it is difficult for children to concentrate for a long time during the vision examination. The Teller visual acuity (TVA) card can be used to evaluate the visual acuity of children, but not all the operations are recorded and can be reviewed.

Continue reading “A human-in-the-loop deep learning paradigm for synergic visual evaluation in children | Article” »

A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients.

Leukemia is a group of blood cancers that results in excess amounts of white blood cells. There are both chronic forms of leukemia that progress slowly over many years and acute types of leukemia that evolve rapidly. AML affects more than 20,000 people in the United States each year, and the mortality rate is high especially in older patients.

One of the most common drugs to treat AML is cytarabine (ara-C), a cytotoxic drug that interferes with DNA replication. However, many patients do not respond to the treatment because their leukemic cells express high levels of the enzyme SAMHD1, which breaks down the active metabolite of cytarabine, ara-CTP. These patients have a significantly worse survival rate than patients with low leukemic levels of SAMHD1. Therefore, one promising strategy to improve the treatment of AML is to inhibit the effects of this enzyme on cytarabine.